Loading company…
Tsukuba-based TNAX Biopharma develops antibody therapeutics for intractable diseases such as acute kidney injury and ischemic stroke.
Founded in 2018 and based in Tsukuba, Japan, TNAX Biopharma develops antibody therapeutics for cardiac surgery-associated acute kidney injury (CSA-AKI) and acute ischemic stroke (AIS). It collaborates with the University of Tsukuba and targets hospitals and healthcare systems in the United States and Europe. The company raised JPY 500 million in Series A funding on November 30, 2018, from Mitsubishi UFJ Capital, JAFCO Group and Nissay Capital, with a valuation of JPY 911.059 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in